Digital biomarkers are bringing new levels of speed and accuracy to the world of Parkinson’s disease clinical trials, producing better data with the potential to accelerate clinical trial timelines with increasingly confident decisions.
Koneksa stands at the forefront of this evolution, developing and validating digital biomarkers enhanced by robust, validated, and patented algorithms designed to support early detection and specific therapeutic considerations for Parkinson’s disease research. With our configurable, cloud-based SaaS platform, Koneksa is uniquely positioned to provide advanced therapeutic effect-detection solutions that enable quicker, more actionable results for Parkinson’s disease trials.
What We Offer Parkinson’s Research
Our science-driven approach produces highly specialized digital biomarkers designed for faster, more comprehensive data collection. They offer the promise of earlier signal detection, exceptional patient compliance, and more complete digital phenotyping of each patient, creating unique data sets that yield new and valuable insights.
Our digital measures empower sponsors with objective remote data collection that minimizes human bias and rater-based errors. Our digital measurement solutions support an innovative new approach to data collection, compared to traditional subjective in-clinic assessments that depend on the difficult task of rating and quantifying tremor levels, gait and balance changes, and other key clinical aspects of Parkinson’s disease. Our digital biomarkers garner timely, accurate measures that matter for your trial, giving you deeper insights at every level.
With extensive regulatory experience showing proven success and unique expertise, our work in Parkinson’s disease trials provides targeted benefits that offset the challenges inherent in traditional neuroscience trials:
Seamless remote data collection leveraging advanced digital health technologies — potential to lower patient burden and improve patient compliance
A dynamic, device-agnostic platform — crucial for Parkinson’s disease with its complex symptoms and the diversity of potential clinical endpoints
A high standard for data quality — Koneksa’s digital measures are remote, objective, and more frequently collected than other standard measures — offering PD researchers a more comprehensive clinical understanding of PD patients’ everyday experiences
Evidence that guides future success in Parkinson’s research — thorough data sets that enhance clinical development decision making and de-risk your Parkinson’s R&D portfolio and future trial protocols alike
Clearer data capture — faster, more comprehensive data for more confident decision making
More robust patented algorithms — aligned with innovative capabilities to produce better data in less time
The Future of Parkinson’s Disease Research Starts Here
Koneksa is leading digital biomarker development. We fully leverage our own scientific expertise and that of sponsors to define and transform how digital measurement solutions are leveraged to unlock value throughout the life sciences ecosystem … in a precise and clinically robust manner.
Going far beyond just eCOAs, our offerings include user-friendly, app-based functional assessments, passively collected wearable sensor data, and a configurable SaaS study execution platform to support seamless device provisioning, data integration, and compliance monitoring.
The future of Parkinson’s research will be defined by continuous remote data collection that not only respects the needs of Parkinson’s patients, but produces more meaningful everyday clinical insights than point-in-time in-clinic measures.
It will be defined by better data and better results — made possible by Koneksa’s digital biomarkers.
A Revolutionary Digital Biomarker to Improve Data in Parkinson’s Disease Research
Koneksa helped develop a digital endpoint instrument for Parkinson’s disease research to improve data collection and management, accelerate therapeutic development, and ease study participation burdens for patients.
Explore this novel endpoint solution and its implications for the future of Parkinson’s disease research.